LitCovid-sentences  

PMC:7600245 / 36076-37609 JSONTXT 7 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T267 0-112 Sentence denotes Danoprevir (Ganovo) is an orally bioavailable 15-membered macrocyclic peptidomimetic antiviral drug (Figure S4).
T268 113-195 Sentence denotes It is an inhibitor of NS3/4A HCV protease, an important processing enzyme complex.
T269 196-257 Sentence denotes It inhibits the protease with an IC50 value of 0.29 nM [112].
T270 258-321 Sentence denotes It was approved in China in 2018 to treat chronic HCV patients.
T271 322-405 Sentence denotes At higher concentrations, it also appears to inhibit the aspartate protease of HIV.
T272 406-545 Sentence denotes The NS3/4A protease of HCV is claimed to share a certain level of structural and/or functional similarity to the protease(s) of SARS-CoV-2.
T273 546-657 Sentence denotes Thus, HCV protease inhibitors, including danoprevir, have been proposed as potential therapeutics for COVID-19.
T274 658-954 Sentence denotes This has also been supported by computational work which indicated that HCV protease inhibitors have high binding affinity to 3CLpro of SARS-CoV-2 [113] and by in vitro and clinical studies which showed that patients with SARS-CoV or MERS-CoV may benefit from HCV protease inhibitors [88,90,114].
T275 955-1157 Sentence denotes Currently, danoprevir in combination with ritonavir, is being evaluated in two clinical trials (NCT04345276; n = 10) and (with nebulized INF; NCT04291729; n = 11) for the treatment of COVID-19 patients.
T276 1158-1334 Sentence denotes As mentioned earlier, ritonavir is an antiviral and pharmacokinetic booster that extends the systemic exposure of patients to potential therapeutic concentration of danoprevir.
T277 1335-1533 Sentence denotes In fact, a recent clinical study results under review has indicated that danoprevir/ritonavir combination alleviated the symptoms in COVID-patients and accelerated their recovery in 4–12 days [115].